Ultime notizie per Pacer US Export Leaders ETF (ARCA:PEXL)

Technology

Consumer Cyclical

Healthcare

Basic Materials

Industrials

Energy

Consumer Defensive

Communication Services

The fund invests at least 80% of its total assets (exclusive of collateral held from securities lending) in the component securities of the index. The index uses an objective, rules-based methodology to measure the performance of an equal weight portfolio of approximately 100 large- and mid-capitalization U.S. companies with a high percentage of foreign sales and high free cash flow growth. Free cash flow is a company cash flow from operations minus its capital expenditures. The fund is non-diversified.

Repligen Corp Common Stock Usd.01

Tesla, Inc.

Baker Hughes Inc

Howmet Aerospace

Concentrix Corporation

Iqvia Holdings Inc.

Fmc Corp.

Accenture PLC Cl A

GXO Logistics, Inc.

Royal Gold Inc Rgld

Uber Technologies Inc

General Electric Co.

Abbott Laboratories

Ralph Lauren Corp. Class A

Genpactltd.

Jabil Circuit Inc 

Fortinet, Inc.

Teledyne Technologies Inc

Cnh Industrial Nv Ord Eur.01 **Qualifying Common Shares**

Duolingo Inc

Crocs Inc

Hess Corp.

Booking Holdings, Inc.

Newmarket Corp Common

Nov Inc

Corteva Inc.

Exxonmobil Corp.

Amphenol Corp. Class A

Netflix, Inc., Long Equities

Cadence Design Systems Inc.

Mosaic Co

Pacer US Export Leaders ETF

Macro Economic Events

News

Economics

Federal Reserve

Fed's Barr Said Disruptions to Supply Networks Can Have Long and Lasting Impact on Prices and Output; Tariffs Could Create Persistent Upward Pressure on Inflation

Billionaire investor Bill Ackman opened up about the most painful chapter of his career—the collapse of his $4 billion investment in Valeant Pharmaceuticals. In a candid interview, he explained how the disaster nearly wrecked his firm, his finances, and his personal life.
What Happened: "We were not a passive investor, but we became a passive investor," Ackman said, calling Valeant "a very unusual investment for us." Unlike his typical hands-on approach, Pershing Square stood by as Valeant's acquisition-driven model fell apart. As the stock collapsed, investors began shorting Ackman&#8217;s other positions, compounding the damage. "I thought we could lose the business," he admitted on the Lex Fridman podcast last year.
At the same time, Ackman was dealing with a divorce, a lawsuit from a shareholder, and an attempt by Elliott Management to take control of his publicly traded investment vehicle. To fend off the takeover, he borrowed $300 million from JPMorgan and personally bought the shares needed to maintain control.
See Also: <a href="https://www.benzinga.com/news/global/25/05/45215257/bill-ackman-calls-tariffs-a-one-time-reset-warns-prolonged-china-fight-could-drag-market-slump-to-q2">Bill Ackman Calls Tariffs A &#8216;One Time Reset,&#8217; Warns Prolonged China Fight Could Drag Market Slump To Q2</a>
Why It Matters: The experience left him shaken but ultimately changed his approach. "There was a period of time where I didn't think I was going to make it," he said. In response, he etched Pershing Square's investment principles in stone and gave copies to every employee. 
Reflecting on the aftermath, Ackman said: "If you're making progress each day, you're in a good place. If you're not making progress each day, you're in a very bad place." The Valeant saga pushed him to refocus on process, discipline, and long-term thinking. From near collapse to recovery, Ackman's story is one of personal and professional resilience. "It was about love, it was about people believing in me, it was about sticking to it, it was about getting up every day," he said.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Bill Ackman&#039;s lowest point: $4 billion dollar loss &#x7C; Lex Fridman Podcast Clips" width="500" height="281" src="https://www.youtube.com/embed/TK60sFs2Cyo?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45219671/bill-ackmans-900m-boost-could-lift-howard-hughes-stock-above-key-technical-barrier-ahead-of-q1-earnings">Bill Ackman&#8217;s $900M Boost Could Lift Howard Hughes Stock Above Key Technical Barrier Ahead Of Q1 Earnings</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Success Stories

Bill Ackman Took A $4 Billion Hit But Says 'Making Progress Each Day' Was Key To Recovering From The Valeant Disaster

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $1.59 per share. This is a 63.92 percent increase over earnings of $0.97 per share from the same period last year. The company reported $373.70 million in sales this quarter. This is a 25.75 percent increase over sales of $297.18 million the same period last year.

Earnings

National Healthcare Q1 Adj. EPS $1.59 Up From $0.97 YoY, Sales $373.70M Up From $297.18M YoY

Telsey Advisory Group analyst Dana Telsey maintains Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) with a Market Perform and lowers the price target from $3 to $1.25.

Price Target

Analyst Ratings

LESL

Telsey Advisory Group Maintains Market Perform on Leslies, Lowers Price Target to $1.25

Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.73) by 2.74 percent. This is a 94.21 percent increase over losses of $(12.27) per share from the same period last year.

Earnings Beats

BOLD

Boundless Bio Q1 EPS $(0.71) Beats $(0.73) Estimate

Telsey Advisory Group analyst Dana Telsey maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and maintains $92 price target.

Telsey Advisory Group Maintains Outperform on Tapestry, Maintains $92 Price Target

Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $1.97 by 52.28 percent. This is a 134.38 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $664.17 million which beat the analyst consensus estimate of $597.69 million by 11.12 percent. This is a 34.72 percent increase over sales of $493.00 million the same period last year.

Ubiquiti Q3 Adj. EPS $3.00 Beats $1.97 Estimate, Sales $664.17M Beat $597.69M Estimate

1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) sees Q2 sales of $21.200 million-$22.500 million vs $22.62 million analyst estimate.

Guidance

DIBS

1stdibs.com Sees Q2 Sales $21.200M-$22.500M vs $22.62M Est

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Prothena Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, Prothena posted weaker-than-expected quarterly results. &#8220;We continue to meaningfully advance our wholly-owned and partnered programs across our protein dysregulation portfolio during this transformative year for Prothena. Most notably in 2025 we anticipate topline data in 2Q from the confirmatory Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis, conducted under a SPA agreement with the FDA with a primary endpoint of time to all-cause mortality at a statistical significance level of 0.10,&#8221; said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. The company's stock fell around 31% over the past month and has a 52-week low of $7.01.</li>
<li>RSI Value: 21.9</li>
<li>PRTA Price Action: Shares of Prothena fell 2.6% to close at $7.10 on Thursday.</li>
<li>Edge Stock Ratings: 5.29 Momentum score with Value at 79.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PRTA"><img loading="lazy" decoding="async" width="486" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png" alt="" class="wp-image-909704" style="width:347px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96-300x104.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure>
<h3 class="wp-block-heading">Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 7, RxSight posted mixed quarterly results. &#8220;The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,&#8221; said Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/RXST">has a 52-week low</a> of $13.22.</li>
<li>RSI Value: 28.8</li>
<li>RXST Price Action: Shares of Rxsight dipped 11.2% to close at $13.23 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">RXST stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="917" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png" alt="" class="wp-image-909712" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-768x693.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. "In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion," said Doug Ingram, CEO of Sarepta Therapeutics. The company's stock fell around 42% over the past five days and has a 52-week l<a href="https://www.benzinga.com/quote/SRPT">ow of $35.4</a>6.</li>
<li>RSI Value: 23.2</li>
<li>SRPT Price Action: Shares of Sarepta Therapeutics fell 0.5% to close at $36.52 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">SRPT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="876" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png" alt="" class="wp-image-909714" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-768x730.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

PRTA

RXST

SRPT

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

WIIM

WOLF

Wolfspeed shares are trading lower. The company reported mixed Q3 financial results

HUBS

HubSpot shares are trading lower after the company reported Q1 financial results. The company issued Q2 adjusted EPS guidance below estimates.

Needham analyst Mayank Tandon maintains Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) with a Buy and raises the price target from $2 to $2.5.

LPRO

Needham Maintains Buy on Open Lending, Raises Price Target to $2.5

FLWS

1-800-FLOWERS.COM shares are trading lower after the company reported worse-than-expected Q3 financial results.

Telsey Advisory Group analyst Dana Telsey maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Market Perform and lowers the price target from $9 to $8.

PTON

Telsey Advisory Group Maintains Market Perform on Peloton Interactive, Lowers Price Target to $8

LASR

nLIGHT shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

CARG

CarGurus shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and issued Q2 adjusted EPS guidance above estimates.

CLSD

Clearside Biomedical Says Its Data Got Featured In Six Presentations At Association For Research in Vision and Ophthalmology 2025 Meeting

Sweetgreen shares are trading lower after the company reported Q1. Also, the company cut its FY25 sales guidance below estimates.

TTD: 17% &#x7C; <a href="https://www.benzinga.com//node/45314085">Trade Desk shares are trading higher after the company reported better-than-expected Q1 financial results.</a>
&nbsp;
PINS: 17% &#x7C; <a href="https://www.benzinga.com//node/45314075">Pinterest shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance with its midpoint above estimates. Also, Pinterest's reported an increase in its monthly average users.</a>
&nbsp;
VEEE: -44% &#x7C; <a href="https://www.benzinga.com//node/45303240">VEEE stock has given up its prior loss. Twin Vee PowerCats shares were trading lower after the company announced a proposed offering of common stock. The company also reported Q1 financial results</a>

Movers

PINS

VEEE

Market-Moving News for May 9th

Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) affirms FY2025 sales outlook from $870.00 million-$910.00 million to $870.00 million-$910.00 million vs $799.17 million estimate.

GOGO

Gogo Affirms FY2025 Sales Guidance of $870.00M-$910.00M vs $799.17M Est

Comments

Pacer US Export Leaders ETF

Notizie

Ultime notizie per Pacer US Export Leaders ETF (ARCA:PEXL)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO